Evidence map›Paper›PMID 33852979›Full record

ArticleAtencion primaria

[Basic aspects of COVID-19 for management from primary care].

José María Molero-García, Javier Arranz-Izquierdo, María Isabel Gutiérrez-Pérez, Jesús María Redondo Sánchez

Abstract read
In one paragraph

Article in Atencion primaria. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

José María Molero-GarcíaCS San Andrés, DA CENTRO (SERMAS), Grupo de trabajo de enfermedades infecciosas de SemFYC, Madrid, España. Electronic address: jmolerog@gmail.com.
Javier Arranz-IzquierdoInstituto de Investigación Sanitaria de Illes Balears (Idisba), CS Escola Graduada, Ibsalut, Palma de Mallorca, Illes Balears, Grupo de trabajo de enfermedades infecciosas de SemFYC, Illes Balears, España.
María Isabel Gutiérrez-PérezCS Delicias I (GAP Oeste) Valladolid, Coordinadora del Grupo de trabajo de enfermedades infecciosas de SemFYC, Valladolid, España.
Jesús María Redondo SánchezCS Ramón y Cajal, DA OESTE (SERMAS), Grupo de trabajo de enfermedades infecciosas de SoMaMFyC, Alcorcón, España.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 is transmitted from person to person by inhalation or contact with respiratory droplets and aerosols. The median incubation period is 5.1 days. Fever, dry cough, dyspnea and fatigue are the most common symptoms. Almost half of the cases are asymptomatic. The spectrum of disease varies from mild (81%) to critical (5%). Older age, male gender and comorbidities negatively impact on the severity and mortality of COVID-19. The diagnosis of acute COVID-19 is made with RT-PCR or antigenic detection tests. In hospital patients, remdesivir reduces recovery time. Oral steroids are recommended for severe or critical cases requiring oxygen therapy or mechanical ventilation. Thromboprophylaxis is recommended in all severe and non-severe cases with high thrombotic risk. Antibiotherapy is limited to cases of high suspicion of bacterial superinfection. Mild-moderate and severe cases after discharge from hospital should be clinically monitored for a minimum period of two weeks.

Indexed as

AftercareAsymptomatic DiseasesCombined Modality TherapyCOVID-19COVID-19 TestingHumansPrimary Health CareSeverity of Illness IndexSpainCOVID-19COVID-19 diagnostic testingCOVID-19 drug treatmentCOVID prolongadoDiagnósticoFamily practiceLong COVIDMedicina de familiaTratamiento farmacológico COVID-19

Identifiers

PMID33852979
PMCPMC7762708

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.